Mirion Technologies Inc

Mirion Technologies Inc(MIR)の株式分析

$18.620

+2.078 (+11.16%)終値時点

Loading chart…
高値
18.765
始値
16.910
出来高加重平均価格
18.05
出来高
8.72M
時価総額
2.48B
安値
16.750
売買代金
157.40M
EV/EBITDA(TTM)
19.53

Mirion Technologies, Inc. is a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets. The Company's segments include Medical, and Nuclear & Safety. The Medical segment includes products and services for radiation therapy, nuclear medicine and personal dosimetry. This segment’s principal product offering is in Radiation Therapy Quality Assurance, which includes solutions for calibrating and/or verifying imaging, treatment machine, patient treatment plan, and patient treatment accuracy. The Nuclear & Safety segment includes products and services focused on addressing critical radiation safety, measurement and analysis applications across nuclear energy, laboratories and research and other industrial markets such as defense. For nuclear power plants (NPPs), it sells products and services for use at any stage of their life (construction, operation, decommissioning and dismantling).

www.mirion.com

AI分析 of Mirion Technologies Inc (MIR)

中立

Mirion Technologies is currently not a strong buy due to its low RSI of 33.18 and a significant year-to-date decline of 37.85%. However, the stock has shown impressive annual revenue growth of 11.7% over the past two years, which suggests potential for recovery. The main risk is the high P/E ratio of 150.43, indicating that the stock may be overvalued at its current price of $14.81.

バリュエーション指標

Mirion Technologies Inc(MIR)の現在の予想PERは0.00で、5年平均は27.10です。

予想PER

大幅な割安
5年平均 P/E
27.10
現在のP/E
0.00
割高
35.12
割安
19.08

予想EV/EBITDA

適正
5年平均 EV/EBITDA
16.55
現在のEV/EBITDA
19.53
割高
21.18
割安
11.93

予想PSR

適正
5年平均 P/S
2.94
現在のP/S
3.14
割高
4.02
割安
1.86

Alphio AI による MIR の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%MIR

$21.71

シナリオ価格

基

基本

基本 · 50%MIR

$18.61

シナリオ価格

弱

弱気

弱気 · 25%MIR

$14.31

シナリオ価格

MIR を保有するクジラ

M

Maverick Capital, Ltd.

+ を保有MIR

+2.83%

3か月リターン

A

Australian Foundation Investment Company Limited

+ を保有MIR

+0.82%

3か月リターン

K

Kuwait Investment Authority

+ を保有MIR

+0.65%

3か月リターン

C

Congress Asset Management Company, LLP

+ を保有MIR

-3.51%

3か月リターン

O

Omega Advisors, Inc.

+ を保有MIR

-4.65%

3か月リターン

D

Davidson Kempner Capital Management LP

+ を保有MIR

-6.00%

3か月リターン

イベントタイムライン

2026-10-27 (ET)

16:30:00

Mirion Reports Q3 Revenue of $277.8M, Beating Expectations

16:30:00

Raises FY26 Revenue Growth to 24%-25%

2026-08-31 (ET)

16:30:00

Mirion Technologies Approves $250 Million Share Repurchase Program

2026-07-28 (ET)

16:30:00

Company Reports Q2 Revenue of $266.8M

ニュース

MIR のよくある質問 — Alphio AI が回答

Mirion Technologies, Inc. is a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets. The Company's segments include Medical, and Nuclear & Safety. The Medical segment includes products and services for radiation therapy, nuclear medicine and personal dosimetry. This segment’s principal product offering is in Radiation Therapy Quality Assurance, which includes solutions for calibrating and/or verifying imaging, treatment machine, patient treatment plan, and patient treatment accuracy. The Nuclear & Safety segment includes products and services focused on addressing critical radiation safety, measurement and analysis applications across nuclear energy, laboratories and research and other industrial markets such as defense. For nuclear power plants (NPPs), it sells products and services for use at any stage of their life (construction, operation, decommissioning and dismantling). It operates in the Industrials sector (MEASURING & CONTROLLING DEVICES, NEC industry).

Mirion Technologies is currently not a strong buy due to its low RSI of 33.18 and a significant year-to-date decline of 37.85%. However, the stock has shown impressive annual revenue growth of 11.7% over the past two years, which suggests potential for recovery. The main risk is the high P/E ratio of 150.43, indicating that the stock may be overvalued at its current price of $14.81.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める